Search Results - "LARSON, Steven M"

Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe by Phillips, Evan, Penate-Medina, Oula, Zanzonico, Pat B, Carvajal, Richard D, Mohan, Pauliah, Ye, Yunpeng, Humm, John, Gönen, Mithat, Kalaigian, Hovanes, Schöder, Heiko, Strauss, H William, Larson, Steven M, Wiesner, Ulrich, Bradbury, Michelle S

“…A first-in-human clinical trial of ultrasmall inorganic hybrid nanoparticles, "C dots" (Cornell dots), in patients with metastatic melanoma is described for…”
Get more information

Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen by Evans, Michael J, Smith-Jones, Peter M, Wongvipat, John, Navarro, Vincent, Kim, Sae, Bander, Neil H, Larson, Steven M, Sawyers, Charles L

“…Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with…”
Get full text

Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer by RATHKOPF, Dana E, MORRIS, Michael J, FLEISHER, Martin, LARSON, Steven M, SAWYERS, Charles L, SCHER, Howard I, FOX, Josef J, DANILA, Daniel C, SLOVIN, Susan F, HAGER, Jeffrey H, RIX, Peter J, CHOW ANEVAL, Edna, CHEN, Isan, GÖNEN, Mithat

“…ARN-509 is a novel androgen receptor (AR) antagonist for the treatment of castration-resistant prostate cancer (CRPC). ARN-509 inhibits AR nuclear…”
Get full text

Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3 by Ahmed, Mahiuddin, Cheng, Ming, Zhao, Qi, Goldgur, Yehuda, Cheal, Sarah M., Guo, Hong-Fen, Larson, Steven M., Cheung, Nai-Kong V.

“…B7-H3 (CD276) is both an inhibitory ligand for natural killer cells and T cells and a tumor antigen that is widely expressed among human solid tumors…”
Get full text

Non-invasive mapping of deep-tissue lymph nodes in live animals using a multimodal PET/MRI nanoparticle by Thorek, Daniel L. J., Ulmert, David, Diop, Ndeye-Fatou M., Lupu, Mihaela E., Doran, Michael G., Huang, Ruimin, Abou, Diane S., Larson, Steven M., Grimm, Jan

“…The invasion status of tumour-draining lymph nodes (LNs) is a critical indicator of cancer stage and is important for treatment planning. Clinicians currently…”
Get full text

Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts by BRENTJENS, Renier J, SANTOS, Elmer, NIKHAMIN, Yan, YEN, Raymond, MATSUSHITA, Maiko, LA PERLE, Krista, QUINTAS-CARDAMA, Alfonso, LARSON, Steven M, SADELAIN, Michel

“…Purpose: Human T cells targeted to the B cell–specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor (CAR), termed 19z1,…”
Get full text

Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results by Morris, Michael J, Molina, Arturo, Small, Eric J, de Bono, Johann S, Logothetis, Christopher J, Fizazi, Karim, de Souza, Paul, Kantoff, Philip W, Higano, Celestia S, Li, Jinhui, Kheoh, Thian, Larson, Steven M, Matheny, Shannon L, Naini, Vahid, Burzykowski, Tomasz, Griffin, Thomas W, Scher, Howard I, Ryan, Charles J

“…Progression-free survival (PFS) in metastatic castration-resistant prostate cancer (mCRPC) trials has been inconsistently defined and poorly associated with…”
Get full text

Bone Scan Index: A Quantitative Treatment Response Biomarker for Castration-Resistant Metastatic Prostate Cancer by Dennis, Elizabeth R, Jia, Xiaoyu, Mezheritskiy, Irina S, Stephenson, Ryan D, Schoder, Heiko, Fox, Josef J, Heller, Glenn, Scher, Howard I, Larson, Steven M, Morris, Michael J

“…There is currently no imaging biomarker for metastatic prostate cancer. The bone scan index (BSI) is a promising candidate, being a reproducible, quantitative…”
Get full text

Paradigms for Precision Medicine in Epichaperome Cancer Therapy by Pillarsetty, Nagavarakishore, Jhaveri, Komal, Taldone, Tony, Caldas-Lopes, Eloisi, Punzalan, Blesida, Joshi, Suhasini, Bolaender, Alexander, Uddin, Mohammad M., Rodina, Anna, Yan, Pengrong, Ku, Anson, Ku, Thomas, Shah, Smit K., Lyashchenko, Serge, Burnazi, Eva, Wang, Tai, Lecomte, Nicolas, Janjigian, Yelena, Younes, Anas, Batlevi, Connie W., Guzman, Monica L., Roboz, Gail J., Koziorowski, Jacek, Zanzonico, Pat, Alpaugh, Mary L., Corben, Adriana, Modi, Shanu, Norton, Larry, Larson, Steven M., Lewis, Jason S., Chiosis, Gabriela, Gerecitano, John F., Dunphy, Mark P.S.

“…Alterations in protein-protein interaction networks are at the core of malignant transformation but have yet to be translated into appropriate diagnostic…”
Get full text

Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival by Vargas, Hebert Alberto, Wassberg, Cecilia, Fox, Josef J, Wibmer, Andreas, Goldman, Debra A, Kuk, Deborah, Gonen, Mithat, Larson, Steven M, Morris, Michael J, Scher, Howard I, Hricak, Hedvig

“…To compare the features of bone metastases at computed tomography (CT) to tracer uptake at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography…”
Get full text

Histopathologic characterization of radioactive iodine‐refractory fluorodeoxyglucose‐positron emission tomography‐positive thyroid carcinoma by Rivera, Michael, Ghossein, Ronald A., Schoder, Heiko, Gomez, Daniel, Larson, Steven M., Tuttle, R. Michael

“…BACKGROUND. Radioactive iodine‐refractory (RAIR) 18F‐fluorodeoxyglucose (FDG)‐positron emission tomography (PET) positive thyroid carcinomas represent the…”
Get full text

Positron emission tomography for prostate, bladder, and renal cancer by Schöder, Heiko, Larson, Steven M.

“…Prostate cancer, renal cancer, bladder, and other urothelial malignancies make up the common tumors of the male genitourinary tract. For prostate cancer,…”
Get full text

Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer by McDevitt, Michael R., Thorek, Daniel L. J., Hashimoto, Takeshi, Gondo, Tatsuo, Veach, Darren R., Sharma, Sai Kiran, Kalidindi, Teja Muralidhar, Abou, Diane S., Watson, Philip A., Beattie, Bradley J., Timmermand, Oskar Vilhemsson, Strand, Sven-Erik, Lewis, Jason S., Scardino, Peter T., Scher, Howard I., Lilja, Hans, Larson, Steven M., Ulmert, David

“…Human kallikrein peptidase 2 (hK2) is a prostate specific enzyme whose expression is governed by the androgen receptor (AR). AR is the central oncogenic driver…”
Get full text

Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-d-Glucose-Positron Emission Tomography Scanning by Robbins, Richard J., Wan, Qiang, Grewal, Ravinder K., Reibke, Roland, Gonen, Mithat, Strauss, H. William, Tuttle, R. Michael, Drucker, William, Larson, Steven M.

“…Context/Objective: Approximately 15% of thyroid cancer patients develop subsequent metastases. The clinical course of patients with metastatic thyroid…”
Get full text

Integrated Positron Emission Tomography/Computed Tomography May Render Bone Scintigraphy Unnecessary to Investigate Suspected Metastatic Breast Cancer by MORRIS, Patrick G, LYNCH, Colleen, FEENEY, John N, PATIL, Sujata, HOWARD, Jane, LARSON, Steven M, DICKLER, Maura, HUDIS, Clifford A, JOCHELSON, Maxine, MCARTHUR, Heather L

“…Although the accurate detection of osseous metastases in the evaluation of patients with suspected metastatic breast cancer (MBC) has significant prognostic…”
Get full text

PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates by Veach, Darren R, Storey, Claire M, Lückerath, Katharina, Braun, Katharina, von Bodman, Christian, Lamminmäki, Urpo, Kalidindi, Teja, Strand, Sven-Erik, Strand, Joanna, Altai, Mohamed, Damoiseaux, Robert, Zanzonico, Pat, Benabdallah, Nadia, Pankov, Dmitry, Scher, Howard I, Scardino, Peter, Larson, Steven M, Lilja, Hans, McDevitt, Michael R, Thorek, Daniel L J, Ulmert, David

“…Most patients with prostate cancer treated with androgen receptor (AR) signaling inhibitors develop therapeutic resistance due to restoration of AR…”
Get full text

Recurrent patterns of DNA copy number alterations in tumors reflect metabolic selection pressures by Graham, Nicholas A, Minasyan, Aspram, Lomova, Anastasia, Cass, Ashley, Balanis, Nikolas G, Friedman, Michael, Chan, Shawna, Zhao, Sophie, Delgado, Adrian, Go, James, Beck, Lillie, Hurtz, Christian, Ng, Carina, Qiao, Rong, ten Hoeve, Johanna, Palaskas, Nicolaos, Wu, Hong, Müschen, Markus, Multani, Asha S, Port, Elisa, Larson, Steven M, Schultz, Nikolaus, Braas, Daniel, Christofk, Heather R, Mellinghoff, Ingo K, Graeber, Thomas G

“…Copy number alteration (CNA) profiling of human tumors has revealed recurrent patterns of DNA amplifications and deletions across diverse cancer types. These…”
Get full text

Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124 I-cG250) and PET in patients with renal masses: a phase I trial by Divgi, Chaitanya R, Prof, Pandit-Taskar, Neeta, MD, Jungbluth, Achim A, MD, Reuter, Victor E, Prof, Gönen, Mithat, PhD, Ruan, Shutian, PhD, Pierre, Christine, BA, Nagel, Andrew, BS, Pryma, Daniel A, MD, Humm, John, Prof, Larson, Steven M, Prof, Old, Lloyd J, MD, Russo, Paul, Prof

“…Summary Background Preoperative identification of tumour type could have important implications for the choice of treatment for renal cancers. Antibody cG250…”
Get full text

TMSOTf assisted synthesis of 2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine ([18F]FAC) by Gangangari, Kishore K, Humm, John L, Larson, Steven M, Pillarsetty, Naga Vara Kishore

“…[18F]FAC (2'-deoxy-2'-[18F]fluoro-β-D-arabinofuranosylcytosine, 1) is a versatile probe for imaging deoxycytidine kinase (dCK) expression levels in vivo. dCK…”
Get full text

CAR Chase: Where Do Engineered Cells Go in Humans? by Krebs, Simone, Dacek, Megan M, Carter, Lukas M, Scheinberg, David A, Larson, Steven M

“…Chimeric antigen receptor (CAR) - and T-cell receptor (TCR) - modified T-cells are rapidly emerging as a viable treatment option for cancer patients. While…”
Get full text